RxDoctor Payments Data

Stella Lou Lee

Optometrist · New York, NYNPI 1336115658

Payments from drug & device makers

$2,885in general payments, 2019–2025

Across 72 payments — averaging $40.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$683
  • Tarsus Pharmaceuticals, Inc.$414
  • Amgen$358
  • Alcon$235
  • AbbVie$212
  • Biotissue Holdings Inc.$146
  • plus $837 from 11 others

What the payments were for

  • Food & beverage$2,86699%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,885 in reported general payments places this provider in the 80th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$21,923
Medicare patients
68
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine143$90,974
Bepotastine Besilate220$37,690
XiidraLifitegrast46$31,713
BepreveBepotastine Besilate43$22,353
LumiganBimatoprost57$15,907
VyzultaLatanoprostene Bunod18$4,515
Cyclosporine16$3,727
ZerviateCetirizine Hcl14$3,050
Azelastine Hcl124$1,647
Timolol Maleate25$1,078
Travoprost16$752
Latanoprost99$701
Brimonidine Tartrate16$701
Prednisolone Acetate11$549
ErythromycinErythromycin Base14$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$212$106,881200 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$683$36,22864 claims
Eyevance Pharmaceuticals LLCZerviate$124$3,05014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,743 optometrist providers in New York.

Other optometrist in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →